Morgan Stanley analyst Jeffrey Hung raised the firm’s price target on PTC Therapeutics to $32 from $30 and keeps an Equal Weight rating on the shares. The firm’s forecasts are above consensus on Translarna net product revenues and slightly above consensus on Emflaza net product revenue, the analyst tells investors in a Biotechnology group preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
- PTC Therapeutics price target raised to $62 from $52 at Cantor Fitzgerald
- PTC Therapeutics Faces EMA Rejection, Seeks Re-examination
- PTC Therapeutics announces CHMP maintains Translarna negative opinion
- JPMorgan smid & large cap biotech analysts hold analyst/industry conference call